Sentences with phrase «therapeutic mabs»

Finally, his discussion covers the genetic manipulation of induced pluripotent stem cells (iPSCs) to derive NK cells engineered to express modified CD16A, and their potential for improving the efficacy of tumor - targeting therapeutic mAbs.

Therapeutic MAbs are typically made in animal host cells and assembled into Y - shaped complexes.

Not exact matches

One approach to tackle this challenge is to program into the therapeutic antibodies the capability of binding to receptors that can help the MAbs to cross into the brain.

Chen's group has been a pioneer in producing MAbs as therapeutic candidates in plants, including tobacco and lettuce plants.

In vivo prophylactic and therapeutic efficacy of human mAbs against pandemic H1N1 influenza virus.

To determine the therapeutic efficacy of the mAbs, mice were challenged with 3xLD50 of the mouse - adapted pandemic H1N1 virus.

In the case of influenza, mAbs have been shown to provide prophylactic or therapeutic protection in mice and other animal models (Reuman et al., 1983; Sweet et al., 1987; Palladino et al., 1995; Renegar et al., 2004).

These findings highlight the need to (a) induce multiple neutralizing antibody lineages for a protective antibody - based vaccine and (b) the potential need to use combinations of purified mAb in therapeutic or prophylactic settings.

An outlook piece that analyzes data on fully human mAbs, a rapidly growing category of mAbs boasting promising therapeutic advantages, with an eye to trends in their development and approval.

EVEN AS SCIENTISTS CONTINUE TO INNOVATE more powerful mAbs, however, several complications could slow this therapeutic juggernaut.

Demonstration of the therapeutic efficacy of this amyloid - reactive mAb would provide an important proof - of - principle that this form of immunotherapy also could benefit individuals with other types of inherited or acquired amyloid - associated disease.

The development of murine amyloid - reactive monoclonal antibodies (mAbs) has provided another therapeutic approach; namely, passive immunotherapy.

Initially, we conducted this landscaping analysis for MAbs because of the wealth of modeling tools designed for that therapeutic class as well as its broad representation of biologic medicinal products in general.

When monoclonal antibody technology became generally available in 1978, John Shively in Todd's lab, produced a Mab to CEA that after genetic engineering and radiolabeling went into City of Hope patients as both an imaging and therapeutic agent.

Using Direct Analysis of Bioreactor Harvest for Clone Selection and Process Optimization Therapeutic monoclonal antibodies (MAbs) mostly are manufactured using bioengineered mammalian cells cultured in a bioreactor for two to three weeks.